Mycobutin (Rifabutin)

Rifabutin is indicated for infections caused by mycobacterial species and for prophylaxis in high‑risk populations.

• Mycobacterium avium complex (MAC) infection: reduces bacterial load and helps prevent disease progression in immunocompromised patients.
• Tuberculosis (as part of combination therapy): adds bactericidal activity to standard regimens and helps limit resistance.
• Prevention of MAC disease in HIV‑infected patients: lowers the incidence of disseminated MAC when given prophylactically.

• Rifabutin binds to the β‑subunit of bacterial DNA‑dependent RNA polymerase, blocking the initiation of RNA synthesis. This inhibition halts transcription, leading to suppressed protein production and ultimately bacterial cell death. The drug’s activity is selective for mycobacterial organisms, making it effective against Mycobacterium avium complex and Mycobacterium tuberculosis.

Rifabutin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea or vomiting: gastrointestinal discomfort that is usually transient.
• Diarrhea: loose stools that may require fluid replacement.
• Rash or pruritus: skin irritation that can vary in intensity.
• Elevated liver enzymes: mild hepatic enzyme changes detected on routine labs.
• Flu‑like symptoms: fever, chills, and muscle aches.

Serious or Rare Side Effects

• Hepatotoxicity: significant liver injury presenting with jaundice or abdominal pain.
• Neutropenia or leukopenia: reduced white blood cell counts increasing infection risk.
• Severe hypersensitivity: angioedema or Stevens‑Johnson syndrome.
• Visual disturbances: blurred vision or color changes requiring ophthalmologic evaluation.
• Hemolytic anemia in patients with G6PD deficiency: rapid drop in hemoglobin levels.

Before initiating Rifabutin therapy, consider patient‑specific factors and monitoring requirements.

• Pregnancy: Category B – use only if the potential benefit justifies the potential risk to the fetus.
• Liver disease: monitor hepatic function regularly; dose adjustment may be needed.
• Concomitant antiretrovirals: assess for drug‑drug interactions, especially with protease inhibitors.
• Renal impairment: evaluate kidney function; adjust dose if severe dysfunction is present.
• Immunocompromised patients: watch for opportunistic infections and hematologic changes.
• Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Rifabutin can alter the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid)

• Protease inhibitors (e.g., ritonavir): may increase Rifabutin levels, raising toxicity risk.
• Macrolide antibiotics (e.g., clarithromycin, azithromycin): can markedly raise Rifabutin concentrations.

Moderate Interactions (Monitor Closely)

• Antiretroviral agents (e.g., efavirenz, nevirapine): may reduce Rifabutin exposure, potentially compromising efficacy.
• Warfarin: Rifabutin may enhance anticoagulant effect; monitor INR closely.
• Anticonvulsants (e.g., carbamazepine, phenytoin): may lower Rifabutin levels, requiring therapeutic monitoring.